Needham Reiterates Buy on Axsome Therapeutics, Maintains $130 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia reiterates a Buy rating on Axsome Therapeutics (NASDAQ:AXSM) and maintains a $130 price target.
August 06, 2024 | 10:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia reiterates a Buy rating on Axsome Therapeutics and maintains a $130 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $130 price target by a reputable analyst suggests strong confidence in Axsome Therapeutics' future performance. This is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100